Forty Seven, Inc. announced that updated data from its ongoing Phase 1b study evaluating magrolimab in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), including additional efficacy and durability data from a larger number of patients, will be presented in an oral presentation at the 61st American Society of Hematology (ASH) Annual Meeting, which is taking place December 7-10, 2019 in Orlando, Florida. In an additional poster presentation, the Company will present preclinical data demonstrating the potential utility of an all antibody approach utilizing FSI-174, its anti-cKIT antibody, and magrolimab for conditioning bone marrow for hematopoietic stem cell transplantation. Magrolimab is a monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages, thus blocking the "don't eat me" signal used by cancer cells to avoid being ingested by macrophages. Forty Seven, Inc. is initially developing magrolimab, an investigational medicine, for the treatment of patients with MDS, AML, non-Hodgkin’s lymphoma, ovarian cancer and colorectal carcinoma. Magrolimab has been granted Fast Track designation by the FDA for the treatment of MDS and AML, and for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, two forms of B-cell non-Hodgkin's lymphoma. Magrolimab has also been granted Orphan Drug designation by the FDA and European Medicines Agency for the treatment of AML. FSI-174 is a humanized monoclonal antibody targeting cKIT, which is a receptor that is highly expressed on hematopoietic stem cells. Forty Seven, Inc. is initially developing FSI-174 in combination with magrolimab as an all antibody-based, less toxic conditioning regimen for the transplantation of hematopoietic stem cells.